Medicamen Biotech Limited

NSEI:MEDICAMEQ Stock Report

Market Cap: ₹5.7b

Medicamen Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Medicamen Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth17.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce

Sep 28
Medicamen Biotech Limited's (NSE:MEDICAMEQ) P/S Is Still On The Mark Following 41% Share Price Bounce

Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Sep 03
Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00

Aug 16
Medicamen Biotech (NSE:MEDICAMEQ) Is Due To Pay A Dividend Of ₹1.00

These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively

Jul 04
These 4 Measures Indicate That Medicamen Biotech (NSE:MEDICAMEQ) Is Using Debt Extensively

What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You

May 21
What Medicamen Biotech Limited's (NSE:MEDICAMEQ) 28% Share Price Gain Is Not Telling You

More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%

Mar 17
More Unpleasant Surprises Could Be In Store For Medicamen Biotech Limited's (NSE:MEDICAMEQ) Shares After Tumbling 26%

Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Sep 13
Medicamen Biotech (NSE:MEDICAMEQ) Will Pay A Dividend Of ₹1.00

Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 19
Why Medicamen Biotech's (NSE:MEDICAMEQ) Shaky Earnings Are Just The Beginning Of Its Problems

There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price

Dec 03
There's Reason For Concern Over Medicamen Biotech Limited's (NSE:MEDICAMEQ) Price

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medicamen Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:MEDICAMEQ - Analysts future estimates and past financials data (INR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20241,80481N/AN/AN/A
3/31/20241,793109-130-67N/A
12/31/20231,707127N/AN/AN/A
9/30/20231,597133-174-106N/A
6/30/20231,497154N/AN/AN/A
3/31/20231,409148-129-63N/A
12/31/20221,250137N/AN/AN/A
9/30/20221,220137-519N/A
6/30/20221,210143N/AN/AN/A
3/31/20221,154149-4541N/A
12/31/20211,139158N/AN/AN/A
9/30/20211,142150-4499N/A
6/30/20211,125140N/AN/AN/A
3/31/20211,127121-52128N/A
12/31/20201,150110N/AN/AN/A
9/30/20201,174116-2716N/A
6/30/20201,222123N/AN/AN/A
3/31/20201,255133-248128N/A
12/31/20191,353136N/AN/AN/A
9/30/20191,241124N/AN/AN/A
6/30/20191,210123N/AN/AN/A
3/31/20191,227120-11443N/A
12/31/20181,187110N/AN/AN/A
9/30/20181,229117N/AN/AN/A
6/30/20181,183108N/AN/AN/A
3/31/20181,115101N/A-55N/A
12/31/20171,04594N/AN/AN/A
9/30/201796281N/AN/AN/A
6/30/201791265N/AN/AN/A
3/31/201782552N/A36N/A
12/31/201678258N/AN/AN/A
9/30/201672326N/AN/AN/A
6/30/201667318N/AN/AN/A
3/31/20166735N/A62N/A
12/31/2015679-13N/AN/AN/A
9/30/2015667-2N/AN/AN/A
6/30/2015760-1N/AN/AN/A
3/31/20157794N/A-33N/A
12/31/20148160N/AN/AN/A
9/30/2014807-1N/AN/AN/A
6/30/2014738-1N/AN/AN/A
3/31/20147321N/A51N/A
12/31/2013696-7N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MEDICAMEQ's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if MEDICAMEQ's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if MEDICAMEQ's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if MEDICAMEQ's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if MEDICAMEQ's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MEDICAMEQ's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y